TSE:EXE

Extendicare Inc (EXE.TO)

35.45
+0.44 (1.26%)
as of Jun 26, 2026, 4:21:36 pm Market Open.
172 watching
0
Investor Insights
star iconJun 26, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Extendicare Inc (EXE-T) occupies a unique position within the healthcare landscape, particularly benefiting from demographic trends favoring long-term care and home healthcare services. Experts highlight its asset-light approach in real estate and the increasing governmental support for home healthcare, suggesting potential growth opportunities. While there is optimism about its earnings and margin management, some analysts express caution due to market saturation and competitive pressures from well-financed private equity firms, which may already be factored into the stock price. The company's fair dividend policy, which distributes about half of its funds from operations (FFO), adds to its attractiveness, but uncertainty about growth prospects has led some experts to explore alternative investments. Overall, Extendicare's stability in long-term care and the promising future of its home healthcare segment form the crux of its evaluation.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
CSH.UN
BUY

Amazing chart. In prime position to take advantage of the demographic story. More of an asset-light play in real estate. Ontario government's increasing funding to home healthcare providers, and it's the largest player. Managing margins well.

High growth, still has legs to mid-high $30s.

DON'T BUY

This space is now all the rage. A tough business. We are underbuilt, and the demographic wave is coming through. But all that's already in the share price. Be careful, especially with stocks that go parabolic on the chart. There are some very-well-financed private equity players that are hiding supply.

He owns SIS instead.

HOLD

Doesn't follow it closely. Does, however, follow CSH.UN.

Very reasonably valued at 13x when you look at price to FFO. Similar market to CSH.UN, but EXE is a corporation and that makes it unique. (REITs have to pay out more, or there's a punitive tax.) Pays out roughly half of its FFO. Likes the business model. Bouncing back from pandemic. Doesn't own due to growth outlook.

DON'T BUY

Both LTC and home healthcare. Long waitlist for LTC beds, so no risk on earnings side. Very good at managing margins. 

Home healthcare is what's growing -- asset light, so dividend won't be as enticing as with other names. Demographics are on its side, but it's hard for him to assign a NAV to it. He'd focus more on names like CSH.UN and SIA.

HOLD

Focused on LTC in Ontario, also a home healthcare business just in Ontario (which forms 50% of the business). No longer in retirement homes. If you own it, you've done well; continue to hold and collect the yield now south of 4%. If you have strong view of the home healthcare business, you could dip in at a better entry point.

DON'T BUY

This has been an extremely good performance year for long-term-care REITs. Not sure there's much more in terms of capital gains from where we are now. Unless substantial pullback, wouldn't buy now.

DON'T BUY
EXE vs. CSH

EXE operates long-term care facilities which require a lot of capital, while CSH is more senior homes. CSH has been divesting lower-return investments to become more of a pure-play. You can charge whatever rent in a market if there's no competition. The seniors' population keeps growing. CSH is paying down debt, which was high a few years ago. In CSH, the easy money has been made, though. It could be a keeper, or take profits.

WATCH
He's looking at the space, which is attractive. Off the highs. Business is materially tougher, but we need it. Regulatory issues and scrutiny on EXE. Labour situation also difficult. Likes the price, but wants to see more on the business fundamentals.
DON'T BUY
There's always something that stops him from entering the seniors space in REITs: labour, regulator issues, though again demographics are a positive. That isn't a good enough, though. How will governments with huge debts supplement the entire seniors home space? However, EXE is cheap. This space is too volatile.
DON'T BUY

How COVID will effect this industry, retirement homes? He owns Sienna instead. EXE is much more involved in government-funded LTCs. Along with Chartwell, these two companies are under government scrutiny, so they likely do a much better job than private LTCs. Good question how COVID will affect these homes: there may be increased costs to manage the LTCs, and he expects the government to do more oversight, particularly the incompetent LTCs. He prefers Sienna to EXE, because Sienna is a mix of LTCs and retirement homes, while Chartwell is mostly retirement homes, which has more upside but more competitive. Don't buy purely LTCs, like EXE.

COMMENT

Extendicare has a better chart than Chartwell. It has a head-and-shoulder chart movement. If you take into account the general market sell-off, investors need to be forgiving.

WATCH
He likes the aging demographics. It has been clawing itself back after problems in the US and high level debt. They are focused on their home care and supply chain businesses. They are trying to now go capital light. He is starting to look at it. It is trading at a discount, relative to peers.
BUY
The long-term care homes are all similar. Slow growers, good dividend yielders. Payouts are reasonable. Steady stream of income. Hasn't increased dividend for 3 years. Resistant to recessions. Labour and other costs are going up. Yield around 5%.
HOLD
A great demographic pick. He bought in at $7.01 in 2014 and bought in again at $6.62. He liked how they paid down debt and reduced operations in the US. He likes the dividend and thinks there is still good upside -- maybe another 50%. They have been growing organically and by takeover. He would like to see them pay down more debt. Yield 5%
BUY ON WEAKNESS
Enjoys a regulated revenue stream like other retirement homes, so it's fairly safe--but has only 2-5% growth. A long-term hold. Buy at $8, though you can sell it at $10.
Showing 1 to 15 of 237 entries

Extendicare Inc (EXE.TO) Frequently Asked Questions

What is Extendicare Inc stock symbol?

Extendicare Inc is a Canadian stock, trading under the symbol EXE.TO (previously EXE-T on Stockchase) on the Toronto Stock Exchange (EXE-CT). It is usually referred to as TSX:EXE or EXE.TO

Is Extendicare Inc a buy or a sell?

In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on EXE.TO (previously EXE-T on Stockchase). 1 analyst recommended to BUY and 2 analysts recommended to SELL the stock. The latest stock analyst rating is BUY on WEAKNESS. Read the latest stock experts' ratings for Extendicare Inc.

Is Extendicare Inc a good investment or a top pick?

Extendicare Inc was recommended as a Top Pick by Bruce Campbell (1) on 2019-10-29. Read the latest stock experts ratings for Extendicare Inc.

Why is Extendicare Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Extendicare Inc.

Is Extendicare Inc worth watching?

Extendicare Inc is followed by 172 investors on Stockchase and is a trending stock that is worth watching.

What is Extendicare Inc stock price?

On 2026-06-26, Extendicare Inc (EXE.TO) stock closed at a price of $35.45.

Star iconStar iconStar half iconStar empty iconStar empty icon
2.5(4)
Based on 4 expert opinions: 1 buy 1 hold 2 sell